Pharmaceutical and clinical implications of proton pump inhibitors with dual antiplatelet therapies: a systematic review
Abstract
Proton pump inhibitors (PPIs) are frequently co-prescribed with dual antiplatelet therapy (DAPT) agents to mitigate the potential of increased gastrointestinal bleeding associated with antiplatelet therapy. Experimental studies have suggested that certain PPIs, such as omeprazole and esomeprazole, may decrease the antiplatelet effects of P2Y12 inhibitors, especially clopidogrel, and, therefore, may potentiate adverse cardiovascular and cerebrovascular events. Data from randomized controlled trials and observational studies have produced mixed results on the clinical implications of this theory. This comprehensive narrative review aims to provide an in-depth analysis of the interactions between PPIs and dual antiplatelet agents, shedding light on their mechanisms and clinical implications and identifying areas for therapeutic optimization. We also address recent advancements in personalized medicine and the potential role of genetic factors in influencing individual responses to PPIs and antiplatelet drugs to optimize treatment outcomes and minimize adverse effects.
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.